Additional file 9: Figure S8. of EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth

Effects of the pharmacological EPCR blockade in the prometastatic activity of 1833 cells. A. Specificity of anti-EPCR antibodies, RCR252, and its F(ab´)2 fraction, by surface plasmon resonance (SPR). EPCR (500 RU) was immobilized through the anti-EPCR antibody RCR2 (that does not bind in the ligand-receptor domain) on a CM5 chip. The binding of 250 nM of RCR252 and its F(ab´)2 fraction to the EPCR were monitored. A representative experiment is shown. RU resonance units; s, seconds. B. Outline of the experiment (n = 8 per group). C. Photon flux quantification in hind limbs. D. Tumor area quantification in H&E-stained bone sections. E. Osteolytic bone area quantification in X-ray images from day 28 post-injection. F. Representative images of BLI (top), X-rays (middle), and H&E staining (bottom) at day 28 post-injection. All data are represented by mean ± SEM. (PPTX 1540 kb)